BeOne Medicines Ltd.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

BeOne Medicines AG는 종양학 전문 기업으로, 미국, 중국, 유럽 및 전 세계적으로 암 환자를 위한 다양한 치료법을 발굴하고 개발하고 있습니다. 이 회사의 상업화 단계 제품으로는 다양한 혈액암 치료를 위한 Bruton's Tyrosine Kinase (BTK) 소분자 억제제인 BRUKINSA; 다양한 고형암 및 혈액암 치료를 위한 항PD-1 항체 면역치료제인 TEVIMBRA; 다발성 캐슬만병 성인 환자 치료를 위한 SYLVANT; 폐경 전 및 폐경 이행기 여성의 유방암(BC) 및 기타 암 환자를 위한 BAITUOWEI; 그리고 다양한 고형암 치료를 위한 PARTRUVIX가 있습니다. 임상 단계 제품으로는 소분자 Bcl-2 억제제인 Sonrotoclax BGB-11417; 야생형 및 변이형 BTK에 활성을 보이는 BTK 표적 키메라 분해 활성화 화합물 BGB-16673; EGFR 표적 CDAC인 BG-60366; MAT2A 억제제인 BG-89894 (SYH2039); MTA 협력 PRMT5 억제제인 BGB-58067; 항EGFRxMET 삼중특이성 항체인 BG-T187 및 BG-C0902; HPK-1 억제제인 BGB-26808; 항B7H3 ADC인 BGB-C354; 이중특이성 HER2 표적 항체인 Zanidatamab; 항FGFR2b ADC인 BG-C137; Pan-KRAS 억제제인 BGB-53038; 항GPC3x4-1BB 이중특이성 항체인 BGB-B2033; 항MUC1xCD16A 이중특이성 항체인 BGB-B3227; 항CEA ADC인 BG-C477; CDK4 억제제인 BGB-43395; CDK2 억제제인 BG-68